Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - Jefferies downgraded Aberdeen Group (ABDN:LN) (OTC:SLFPY) from Buy to Hold while raising its price target to GBP1.75 from GBP1.65.
The rating change comes ahead of Aberdeen Group’s first-half 2025 results, scheduled for release on July 30 at 07:00 UK time.
Jefferies cited higher costs as the primary reason for reducing its fiscal year 2025 adjusted earnings per share forecast by 10%, despite noting that a recovery in markets since April has positively impacted assets under management and administration.
The firm’s fiscal year 2026 forecasts actually increased slightly, with adjusted operating margin projections approaching Aberdeen’s target of £300 million or more.
Despite raising the price target based on improved 2026 forecasts, Jefferies downgraded the stock following its rally since April.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.